Syncom Formulations Limited (NSE: SYNCOMF) is a trusted pharmaceutical company in India that makes many types of health products. They manufacture active medicines, tablets, capsules, liquids, and special creams to treat different illnesses. The business started in 1995 and has a big, clean factory in Madhya Pradesh. They sell their products safely across India and export them to over twenty-five countries worldwide. By using modern technology, they ensure their healthcare products are completely safe and of the best quality. Today, people and doctors trust them to deliver helpful and affordable healthcare solutions.
Syncom Formulations Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | ₹1,293 Cr |
| ROE | 18.42% |
| P/E Ratio (TTM) | 16.99 |
| EPS (TTM) | 0.81 |
| P/B Ratio | 3.12 |
| Dividend Yield | 0.00% |
| Industry P/E | 36.16 |
| Book Value | 4.41 |
| Debt to Equity | 0.00 |
| Face Value | 1 |
Syncom Formulations Share Price Target 2026
Syncom Formulations share price target for 2026 is expected to range from ₹11 to ₹15. Here are three key factors that could affect the company’s share price in 2026:
- Massive Catalog of Health Products: Syncom makes over 500 different kinds of medicines. They produce tablets, liquids, and capsules to treat simple coughs, stomach aches, and serious heart problems. Since people always need healthcare, selling many different kinds of medicines helps the business make steady money and keeps its share price very stable.
- Selling Medicines to Government Hospitals: The company has been chosen as a trusted supplier to central government hospitals in India. They are also in the final stages of getting approved to supply medicines to the army. Winning these major government contracts guarantees huge, steady sales orders, which makes investors happy and raises the stock value.
- Boosting Factory Production Capacity: Syncom recently upgraded its main factory in Pithampur to increase tablet production by thirty-five percent. They also doubled the capacity of their capsule-making machines to meet growing demand. When factories make more products quickly, the company can sell more goods, leading to bigger profits and a rising stock price.
Syncom Formulations Share Price Target 2027
Syncom Formulations share price target for 2027 is expected to range from ₹16 to ₹22. Here are three key factors that could affect the company’s share price in 2027:
- Strong Demand for Herbal Items: Customers today are looking for natural health options, so Syncom is creating and selling more herbal products. These include special natural remedies for skin problems, stomach acidity, and general wellness. Selling highly popular herbal products opens up new customer markets and boosts the company’s brand image and financial performance.
- Growing Sales to Foreign Countries: The company does not just sell medicine in India; it exports products to countries worldwide. Selling to global buyers brings in foreign money, which is often worth more than domestic currency. As international sales grow, the company becomes less dependent on one country’s economy, which keeps the share price safe.
- Excellent Rise in Net Profits: Over the past few years, the company’s yearly net profit has climbed significantly. In fact, their financial reports showed a massive fifty-five percent jump in total profits for the fiscal year. When a company shows strong profit growth, stock market buyers rush to buy shares, pushing the stock price up.
Syncom Formulations Share Price Target 2030
Syncom Formulations share price target for 2030 is expected to range from ₹48 to ₹60. Here are three key factors that could affect the company’s share price in 2030:
- Very Low and Safe Debt Levels: Some companies borrow huge amounts of money from banks and struggle to pay it back. Syncom operates with very little debt, which means they do not have to pay heavy interest charges. Having a strong, debt-free balance sheet makes the company safe during hard times, attracting big-time investors.
- Growing Indian Pharmaceutical Sector: The entire medicine industry in India is growing rapidly due to better health awareness and larger populations. Since Syncom is an established player, it naturally benefits from this massive nationwide industry growth. General positive feelings about pharma stocks help lift Syncom’s share price along with its competitors.
- Big Investments from Institutional Buyers: Foreign and domestic financial institutions have been increasing their ownership stakes in debt-free Indian stocks like Syncom. When large financial organizations invest their money, it shows they trust the company’s future. This heavy buying support creates stability and prevents the stock price from crashing easily.
Syncom Formulations Share Price Target 2040
Syncom Formulations share price target for 2040 is expected to range from ₹130 to ₹250. Here are three risks & challenges that could affect the company’s share price in 2040:
- Rising Costs of Raw Materials: To make capsules and liquid medicines, the company must buy chemical ingredients and packaging materials. When the prices of these raw ingredients go up globally, making medicine becomes much more expensive. If Syncom cannot raise its product prices quickly, its profit margins will shrink.
- Strict Rules and Quality Checks: Medicine factories must pass extremely strict safety checks from government health departments to keep running. If inspectors find any small mistakes in the factory or product quality, they can halt production instantly. Fixing these regulatory issues costs a lot of money and can damage the company’s reputation.
- Tough Competition in Generic Medicines: There are thousands of pharmaceutical companies in India making similar, low-cost generic drugs. To win customers, companies often lower their prices, which triggers painful price wars. Intense competition makes it very hard for Syncom to keep its prices high enough to earn good profits.
Syncom Formulations Share Price Target 2050
Syncom Formulations share price target for 2050 is expected to range from ₹540 to ₹800. Here are three risks & challenges that could affect the company’s share price in 2050:
- Small-Cap Stock Liquidity Squeeze: Syncom is a relatively small company compared to giant pharma corporations, making it a small-cap stock. During uncertain market times, investors often pull money out of smaller stocks first. This sudden selling can cause the share price to drop much faster than larger, safer stocks.
- Changes in Government Price Controls: The government of India controls the maximum price that companies can charge for essential medicines. If the government decides to lower the price limit on medicines that Syncom makes, the company’s revenue will drop. These unpredictable policy changes create constant financial uncertainty for stock market investors.
- Global Shipping and Currency Risks: Exporting medicines across the ocean requires smooth shipping lines and steady currency rates. High cargo shipping costs or a sudden change in foreign exchange rates can hurt export earnings. Any major trade argument between countries can stop deliveries and reduce the company’s international profits.
Syncom Formulations Share Price Target 2026, 2027, 2028, 2029, 2030, 2040, 2050
| Year | Target Price (₹) |
|---|---|
| 2026 | 11 to 15 |
| 2027 | 16 to 22 |
| 2028 | 24 to 30 |
| 2029 | 32 to 44 |
| 2030 | 48 to 60 |
| 2040 | 130 to 250 |
| 2050 | 540 to 800 |
Also Read: Vidhi Specialty Food Ingredients Share Price Target
Syncom Formulations Shareholding Pattern
| Category | Holding |
|---|---|
| Promoters | 50.57% |
| Retail and Others | 49.32% |
| Foreign Institutions | 0.11% |
Syncom Formulations Key Competitors
Lincoln Pharmaceuticals, Fermenta Biotech, Shukra Pharmaceuticals, Fredun Pharmaceuticals, Jagsonpal Pharmaceuticals, Bajaj Healthcare, Rubicon, Windlas, Suraksha Diagnostic, and GPT Healthcare.
Disclaimer: All the information provided in this article is for educational and infomational purposes only. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
